{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016015","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.485464+00:00","generated_at":"2026-06-24T02:05:16.738028+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reneo Q2 net loss $12.3M; positive LC-FAOD results; STRIDE enrollment two-thirds","bullets":["Net loss $12.3M ($0.50/share) vs $9.2M ($0.43/share) in Q2 2021.","Cash, cash equivalents, and short-term investments ~$127M as of June 30, 2022.","R&D expenses $8.1M (up $1.8M YoY); G&A $4.3M (up $1.4M).","Positive results from REN001 Phase 1b LC-FAOD study; plan to meet regulators.","STRIDE pivotal PMM study enrollment two-thirds complete; on track for year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016015","json":"https://secwatch.observer/filing/0000950170-22-016015.json","markdown":"https://secwatch.observer/filing/0000950170-22-016015.md","text":"https://secwatch.observer/filing/0000950170-22-016015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017022016015/0000950170-22-016015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017022016015/rphm-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:05:16.738028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}